Clinical Pharmacology: 8 High-Yield USMLE Practice Questions
Pharmacology is tested on every USMLE exam. These 8 questions cover the highest-yield drug mechanisms, toxicities, and clinical scenarios — focusing on questions that require integrating mechanism with clinical presentation.
Reviewed for clinical accuracy
Progress Note Editorial · Evidence-based
Updated July 2026
Aligned to current board blueprints
★★★★★4.7(38)
·1.2k students studied this·Medical students & residents
Question 1 of 8Score: 0 / 0
Q1Antiarrhythmics
A 60-year-old with atrial fibrillation is started on amiodarone. Three months later he develops dyspnea and CXR shows bilateral interstitial infiltrates. PFTs show decreased DLCO. The most likely complication is:
Explanation: Amiodarone pulmonary toxicity (APT): most dangerous amiodarone side effect. Occurs in 5-10% of patients. Presents insidiously: progressive dyspnea, dry cough, bilateral interstitial infiltrates on CXR, decreased DLCO on PFTs. Treatment: STOP amiodarone, systemic corticosteroids. Annual monitoring: CXR, PFTs with DLCO, TFTs, LFTs. Amiodarone also causes hypothyroidism (more common) or hyperthyroidism, corneal microdeposits (benign), and hepatotoxicity.
Q2Antidepressants
A patient takes phenelzine (MAO inhibitor) for depression. She eats a large meal of aged cheese and wine at a party and develops severe headache, hypertensive crisis, and diaphoresis. The mechanism is:
Explanation: Tyramine reaction ('cheese effect'): aged cheese, wine, cured meats, soy sauce contain tyramine. Normally, tyramine is broken down by intestinal MAO-A. When MAO is inhibited (phenelzine, tranylcypromine), dietary tyramine enters systemic circulation → displaces norepinephrine from adrenergic nerve terminals → massive NE release → hypertensive crisis. Treatment: phentolamine (alpha-blocker) or nitroprusside. Prevention: avoid tyramine-rich foods on all MAOIs. MAOIs also interact with SSRIs/SNRIs/meperidine → serotonin syndrome.
Q3Antihypertensives
A 55-year-old man with hypertension is started on lisinopril. Two weeks later he develops a dry, persistent cough. The mechanism of this side effect is:
Explanation: ACE inhibitor cough: bradykinin accumulation. ACE normally degrades bradykinin (and substance P); ACE inhibition → bradykinin accumulates in airways → stimulates pulmonary irritant receptors → dry cough. Occurs in 10-15% of patients (more common in Asian patients: 30-40%). Solution: switch to ARB (losartan, valsartan) — ARBs block angiotensin II receptor but do NOT inhibit ACE → bradykinin is still degraded → no cough. Angioedema (rare, more dangerous) is also from bradykinin accumulation — involves tongue/lip/throat — contraindicate all ACEi/ARB if it occurs.
Q4Antihypertensives
A woman in the third trimester of pregnancy is found to have a blood pressure of 162/105. She is started on hydralazine IV. One hour later, her BP is 155/100 and she develops tachycardia. What compensatory mechanism explains the tachycardia?
Explanation: Hydralazine is a direct arterial vasodilator (dilates arterioles via cGMP/K+ channel opening). Its effects: decreases SVR → reduces blood pressure → BAROREFLEX activation detects decreased BP → sympathetic nervous system activation → reflex tachycardia + increased renin release (RAAS activation). This is why hydralazine is typically combined with a beta-blocker (to prevent reflex tachycardia) and a diuretic (to prevent sodium/water retention). In pregnancy, hydralazine and labetalol are the IV antihypertensives of choice for severe-range blood pressures.
Q5Drug Interactions
A patient on warfarin for atrial fibrillation is started on fluconazole for vaginal candidiasis. Three days later, his INR is 6.8. The mechanism is:
Explanation: Warfarin is primarily metabolized by CYP2C9. Fluconazole (and other azole antifungals) potently inhibits CYP2C9 and CYP3A4 → decreased warfarin metabolism → warfarin accumulates → supratherapeutic INR and bleeding risk. This is one of the most important drug interactions on USMLE. Management: hold warfarin, monitor INR closely; consider dose adjustment or alternative antifungal. Other potent CYP2C9 inhibitors: amiodarone, fluoxetine, metronidazole, isoniazid. CYP inducers (rifampin, carbamazepine, phenytoin) DECREASE warfarin effect → subtherapeutic INR.
Q6Antiepileptics
A 28-year-old woman is started on valproic acid for epilepsy. She later becomes pregnant. What is the primary teratogenic risk of valproate?
Explanation: Valproate teratogenicity: neural tube defects (spina bifida aperta, anencephaly) in ~1-2% of exposures in the first trimester, when the neural tube closes. Also associated with fetal valproate syndrome (craniofacial abnormalities, limb defects, cognitive impairment). Valproate is the most teratogenic of the common AEDs — should be avoided in women of childbearing potential when alternative agents are effective. All women on valproate should take folic acid supplementation. Compare: phenytoin → fetal hydantoin syndrome; carbamazepine → neural tube defects (but lower risk than valproate); lithium → Ebstein anomaly.
Q7Diabetes Pharmacotherapy
A 65-year-old man with newly diagnosed type 2 diabetes also has cardiovascular disease (prior MI). What antidiabetic drug has the best evidence for reducing major adverse cardiovascular events (MACE)?
Explanation: Empagliflozin (EMPA-REG OUTCOME trial) and liraglutide (LEADER trial) are the two drugs with the strongest evidence for reducing MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in T2DM patients with established CVD. Current ADA guidelines recommend GLP-1 RA or SGLT2i as preferred add-on to metformin in T2DM with established ASCVD or high ASCVD risk. Sulfonylureas and DPP-4 inhibitors are weight-neutral/weight-gain and lack CVD benefit. Pioglitazone reduces MACE in some studies but causes weight gain, fluid retention, and bladder cancer risk.
Q8Antipsychotics
A patient with schizophrenia on haloperidol develops hyperthermia (40.5°C), 'lead-pipe' rigidity, altered mental status, and elevated CK. BP is fluctuating. The next best step is:
Explanation: Neuroleptic malignant syndrome (NMS): life-threatening emergency from antipsychotic use. Triad: hyperthermia + muscle rigidity ('lead-pipe') + altered mental status + autonomic instability. Elevated CK from muscle breakdown → rhabdomyolysis → renal failure. Treatment: (1) STOP the offending drug immediately; (2) Dantrolene (inhibits sarcoplasmic Ca2+ release → reduces rigidity/hyperthermia); (3) Bromocriptine or amantadine (dopamine agonists — restore dopamine signaling); (4) Aggressive cooling and supportive care (IV fluids for rhabdo). Distinguish from serotonin syndrome (hyperreflexia/clonus/diaphoresis, not lead-pipe rigidity; treat with cyproheptadine).
What is the difference between NMS and serotonin syndrome?
Both are drug-induced hyperthermic emergencies but have key differences: NMS: dopamine antagonist (antipsychotic) cause; gradual onset (days); lead-pipe rigidity (uniform, not hyperreflexia); bradyreflexia; treat with dantrolene + bromocriptine. Serotonin syndrome: serotonergic excess (SSRI + MAOI, or SSRI + tramadol/meperidine/linezolid); rapid onset (hours); neuromuscular findings: clonus (rhythmic, especially ankle clonus), hyperreflexia, diaphoresis; treat with cyproheptadine (5-HT2A antagonist) + benzodiazepines + stop the agent.
Which antidiabetic drugs have proven cardiovascular benefits?
Three drug classes have cardiovascular outcome trial data: (1) SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin): reduce MACE, heart failure hospitalization, and CKD progression. (2) GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide): reduce MACE (particularly stroke with semaglutide), weight loss, no hypoglycemia risk. (3) Pioglitazone (TZD): modest MACE reduction in PROACTIVE trial but causes fluid retention and bladder cancer risk. ADA recommends GLP-1 RA or SGLT2i (not sulfonylurea or DPP-4 inhibitor) when CVD risk reduction is a priority.
Build The Habit
Keep the streak going
Progress Note tracks your accuracy over time and adapts to your weak spots — free to start, no credit card required.